ClinicalTrials.Veeva

Menu

IEEM-Heat and Heart Failure

The University of Texas System (UT) logo

The University of Texas System (UT)

Status

Begins enrollment in 1 month

Conditions

Hyperthermia
Heart Failure

Treatments

Other: Skin-Wetting Trial
Other: Fan Trial
Other: Control Trial

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT06961929
STU20250699
R01AG069005 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

We will test the hypothesis that increasing skin wetness, and thus evaporative cooling, will attenuate the increase in core body temperature and accompanying cardiac stress during heat wave conditions in individuals with congestive heart failure. Secondly, we propose that fan use alone may be possibly detrimental (very hot and dry) depending on the environmental conditions. To accomplish these objectives, individuals with congestive heart failure and otherwise healthy control individuals will be exposed to the simulated heat wave condition (very hot and dry) with the following cooling modalities: A) control trial (no fan or skin wetting), B) skin wetting only trial, and C) fan only trial in a randomized crossover fashion. Thermoregulatory and cardiovascular responses will be evaluated throughout these simulated heat wave exposures.

Primary outcomes variables will be skin and core temperatures, while secondary variables will include measures of cardiovascular stress, myocardial perfusion, heart rate, and echo-based measures of cardiac function.

Enrollment

88 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for healthy control participants:

  • Participants must be free of any significant underlying medical problems based upon a detailed medical history and physical exam, and normal resting electrocardiogram. Participants must be 18+ years. However, since they will be age-matched to individuals with CHF, we anticipate most of the participants will be 45+ years old.

Exclusion Criteria for healthy control participants:

  • Known heart disease; other chronic medical conditions requiring regular medical therapy including cancer, diabetes, neurological diseases, and uncontrolled hypertension, lung disease, etc.; as well as serious abnormalities detected on routine screening. Participants with a body mass index ≥ 35 kg/m2 will be excluded. Current smokers, as well as individuals who regularly smoked within the past 9 months, will be excluded. Subjects who cannot be age and gender matched to an individual in the heart failure group will be excluded.

Inclusion Criteria for Participants with CHF:

  • The participant must have a diagnosis of congestive heart failure (e.g., heart failure with reduced ejection fraction), with the severity categorized as New York Heart Association (NYHA) class II or III. Participants must be 18+ years, though we anticipate that most participants with heart failure will be 45+ years old.

Exclusion Criteria for Participants with CHF:

-Patients who do not have confirmed diagnosis of NYHA class II or III heart failure will be excluded from the clinical group. Potential participants with cancer, diabetes, neurological disease, lung disease, and/or uncontrolled hypertension will be excluded. Potential participants with a left bundle branch block on ECG will be excluded, as well as those with an ejection fraction >40%. Patients on anticoagulant therapy will also be excluded. Participants with a body mass index ≥ 35 kg/m2 will be excluded. Current smokers, as well as individuals who regularly smoked within the past 9 months, will be excluded. Further exclusions will include severe valvular or congenital heart disease, acute myocarditis, NYHA Class IV heart failure, and/or manifest/provocable ischemic heart disease.

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

88 participants in 2 patient groups

Individuals with Congestive Heart Failure (CHF)
Active Comparator group
Treatment:
Other: Control Trial
Other: Fan Trial
Other: Skin-Wetting Trial
Individuals without Congestive Heart Failure (Control)
Active Comparator group
Treatment:
Other: Control Trial
Other: Fan Trial
Other: Skin-Wetting Trial

Trial contacts and locations

0

Loading...

Central trial contact

Craig Crandall, PhD; Erin Harper, BS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems